143 related articles for article (PubMed ID: 38721957)
1. A modified schedule of multiple aeroallergen ultra-rush immunotherapy in perennial allergic rhinitis: safety, efficacy, and T lymphocyte cell population studies.
Ariaee N; Fouladvand A; Mohammadi M; Farid-Hosseini R; Nikpoor AR; Khoshkhui M; Tavakkol-Afshari J; Jabbari-Azad F
Allergol Immunopathol (Madr); 2024; 52(3):65-72. PubMed ID: 38721957
[TBL] [Abstract][Full Text] [Related]
2. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy.
Adamic K; Zidarn M; Bajrovic N; Erzen R; Kopac P; Music E
Wien Klin Wochenschr; 2009; 121(9-10):357-60. PubMed ID: 19562302
[TBL] [Abstract][Full Text] [Related]
3. Safety of multiple aeroallergen rush immunotherapy using a modified schedule.
Temiño VM; Wu P; Konig J; Fahrenholz JM
Allergy Asthma Proc; 2013; 34(3):255-60. PubMed ID: 23676574
[TBL] [Abstract][Full Text] [Related]
4. Safety of rush immunotherapy using a modified schedule: a cumulative experience of 893 patients receiving multiple aeroallergens.
Smits WL; Giese JK; Letz KL; Inglefield JT; Schlie AR
Allergy Asthma Proc; 2007; 28(3):305-12. PubMed ID: 17619559
[TBL] [Abstract][Full Text] [Related]
5. Rush immunotherapy: experience with a one-day schedule.
Sharkey P; Portnoy J
Ann Allergy Asthma Immunol; 1996 Feb; 76(2):175-80. PubMed ID: 8595538
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(3):142-4. PubMed ID: 15946626
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
Rossi RE; Monasterolo G
Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
[TBL] [Abstract][Full Text] [Related]
9. [Observation and analysis of systemic reactions to house dust mite subcutaneous immunotherapy in 362 patients with allergic rhinitis].
Xue JR; Ma J; Qiu CY; Hu ZB; Jiang X; Pan M; Lu MP; Cheng L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 May; 55(5):445-451. PubMed ID: 32842357
[No Abstract] [Full Text] [Related]
10. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
[TBL] [Abstract][Full Text] [Related]
11. Safety of rush immunotherapy to multiple aeroallergens in an adult population.
Harvey SM; Laurie S; Hilton K; Khan DA
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):414-9. PubMed ID: 15104192
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J
Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361
[TBL] [Abstract][Full Text] [Related]
13. A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol.
Fajt ML; Rosenberg SL; Yecies E; Traister RS; Petrov AA
Allergy Asthma Proc; 2017 Jul; 38(4):309-316. PubMed ID: 28668111
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis.
Balaji R; Parasuramalu BG; Chandregowda BV; Gangaboraiah
Allergol Immunopathol (Madr); 2014; 42(3):216-23. PubMed ID: 23481554
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of radioallergosorbent test-based allergen immunotherapy in treatment of perennial allergic rhinitis and asthma.
Yeoh KH; Wang DY; Gordon BR
Otolaryngol Head Neck Surg; 2004 Nov; 131(5):673-8. PubMed ID: 15523447
[TBL] [Abstract][Full Text] [Related]
16. Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts.
Brehler R; Klimek L; Pfaar O; Hauswald B; Worm M; Bieber T
Allergy Asthma Proc; 2010; 31(3):e31-8. PubMed ID: 20615317
[TBL] [Abstract][Full Text] [Related]
17. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
Int Arch Allergy Immunol; 2006; 139(2):153-8. PubMed ID: 16374026
[TBL] [Abstract][Full Text] [Related]
18. [The value and possibilities of immunotherapy in the treatment of allergic rhinitis].
Pfaar O; Hörmann K; Klimek L
MMW Fortschr Med; 2006 Feb; 148(5):28-32. PubMed ID: 16518935
[TBL] [Abstract][Full Text] [Related]
19. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts.
Portnoy J; Bagstad K; Kanarek H; Pacheco F; Hall B; Barnes C
Ann Allergy; 1994 Nov; 73(5):409-18. PubMed ID: 7978533
[TBL] [Abstract][Full Text] [Related]
20. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
